谷氨酸加谷氨酸与GABA的比率作为治疗耐药抑郁症中氨酸反应的预测因素:一项双盲,随机,开放式延伸研究
Yohei Ohtani1, Hideaki Tani2, Shiori Honda3
1Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan; Department of Psychiatry, Minami-Hanno Hospital, Saitama, Japan.
Journal of affective disorders
|May 1, 2025
概括
在背前环状皮层中,谷氨酸-谷氨胺 (Glx) 与GABA的基线比较高,预测治疗耐药抑郁症的胺反应更好. 这种刺激-抑制不平衡可能表明治疗的有效性.
科学领域:
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
- 放射学 放射学是一门学科.
背景情况:
- 治疗耐药性抑郁症 (TRD) 影响了许多患者,只有30%的人对氨酸有反应.
- 在TRD中胺反应的预测因素仍然难以捉摸.
- 激发性-抑制性神经递质失衡是胺的潜在作用机制.
研究的目的:
- 调查在背前环状皮质 (dACC) 中的谷氨酸和谷氨酸 (Glx) 与GABA的基线比率是否可以预测TRD患者的氨酸反应.
- 探索基线Glx/GABA比率与治疗结果之间的关系.
主要方法:
- 一个双盲随机临床试验的探索性分析与一个开放的标签扩展.
- 质子磁共振光谱法用于测量dACC中的Glx和GABA水平在胺治疗前后.
- 一般线性模型评估了基线Glx/GABA比率与17项汉密尔顿抑郁评分表 (HDRS-17) 评分的变化之间的相关性.
主要成果:
- 胺治疗导致双盲 (-4.9) 和开放标签 (-4.9) 期间的HDRS-17得分显著改善.
- 较高的基线dACC Glx/GABA比率与更大的HDRS-17改善有显著的相关性 (p=0.040).
- 在胺组中,治疗后dACC Glx/GABA比率降低与较大的症状改善相关 (p=0.009),与安慰剂组不同.
结论:
- 这些发现表明,dACC中的激发抑制失衡, Glx/GABA比率表明,可能预测胺在TRD中的有效性.
- 这个比率可以作为治疗反应的潜在生物标志物.
- 需要进一步的研究来验证这些发现.
关键词:
(1) H-MRS 是一个H-MRS.激发性/抑制性的平衡.对于GABA来说,这是一个很好的选择.Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx胺基氨酸 (ketamine) 是一种可以预测器预测器治疗耐药性抑郁症的治疗方法更多相关视频
相关概念视频
Antiepileptic Drugs: Glutamate Antagonists
264
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
264
Antiepileptic Drugs: GABAergic Pathway Potentiators
300
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
300


